AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 13 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - People with thalassemia, especially those who have undergone splenectomy, can benefit from vaccination against Haemophilus influenzae type b (Hib), but an effective booster regimen still needs to be established, according to a new report in the Journal of Infectious Diseases.
Though clinicians were aware that these patients were more susceptible to infectious diseases and need vaccinations and antimicrobial prophylaxis, no vaccine protocol for Hib had been established, said R. Cimaz and colleagues in Italy.
They measured Hib antibodies in 57 thalassemia patients, 32 of whom had undergone splenectomy, before and periodically up to three years after Hib vaccination.
Although all patients initially had protective antibodies to Hib (>1 (micro)g/ml), these gradually declined, becoming undetectable in four patients and declining to 0.15-1 (micro)g/ml in two patients by two to three years postvaccination, reported Cimaz and coworkers.
All patients tolerated the Hib vaccine well ("Safety and immunogenicity of a conjugate vaccine against Haemophilus influenzae type b in splenectomized and nonsplenectomized patients ...